Copyright 2002 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2002
We read with interest the article on the neurologic manifestation of Wegener granulomatosis (WG) by de Groot et al,1 which described a prospective series of 128 consecutive patients with WG ascertained between 1991 and 1997 who underwent a standardized neurologic evaluation, including history, examination, electroencephalography, and electrodiagnostic testing. The authors determined that 56 patients (44%) had a peripheral neuropathy: a distal symmetric polyneuropathy in 31 (55%) and multiple mononeuropathy in 25 (45%). Weakness was present in 19 patients with neuropathy (34%), and muscle atrophy occurred in 24 (43%), implying that the neuropathy was purely sensory in more than 50%. All patients were treated with immunosuppressive agents to induce remission (generally oral cyclophosphamide and corticosteroids). The authors reported that whereas patients with multiple mononeuropathy exhibited a significant improvement in disability after treatment, those with a symmetric polyneuropathy did not.
Collins MP, Periquet MI. Prevalence of Vasculitic Neuropathy in Wegener Granulomatosis. Arch Neurol. 2002;59(8):1333-1334. doi: